U.S. agency finds no defect in review of 662,000 Tesla vehicles
By David Shepardson WASHINGTON (Reuters) - The National Highway Traffic Safety Administration (NHTSA) said it would not grant a petition seeking a formal review of 662,000 Tesla vehicles for claims of sudden unintended acceleration (SUA). The U.S
By David Shepardson
WASHINGTON (Reuters) - The National Highway Traffic Safety Administration (NHTSA) said it would not grant a petition seeking a formal review of 662,000 Tesla vehicles for claims of sudden unintended acceleration (SUA).
The U.S. auto safety regulator said its review of the December 2019 petition into 2012-2020 model year Tesla Model S, Model X, Model Y and Model 3 vehicles found the incidents cited "were caused by pedal misapplication. NHTSA found no evidence of fault in the accelerator pedal assemblies, motor control systems, or brake systems that contributed to the cited incidents."
The petition cited 232 complaints to NHTSA, including 203 crashes and the agency opened a formal review into the petition in January 2020.
NHTSA added that "there is no evidence of a design factor contributing to increased likelihood of pedal misapplication. The theory provided of a potential electronic cause of SUA in the subject vehicles is based upon inaccurate assumptions about system design and log data."
Tesla did not immediately respond to a request to comment.
(Reporting by David Shepardson; Editing by Chizu Nomiyama)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Uday Sampath Kumar (Reuters) - Target Corp reported a 17.2% rise in comparable sales for the holiday season on Wednesday as its online sales more than doubled, thanks to faster deliveries and higher demand for home goods, electronics and beauty products.
By Medha Singh and Devik Jain (Reuters) - The S&P 500 and the Nasdaq rose in choppy trading on Wednesday as Intel shares jumped thanks to a change in management while broader sentiment was muted after a recent run to record highs. Intel said it would replace Chief Executive Officer Bob Swan with VMware Inc CEO Pat Gelsinger next month
By Danny Ramos LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine. President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population. Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.